Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Citigroup

Citigroup assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Thursday morning, Marketbeat.com reports. The brokerage issued a neutral rating and a $895.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on REGN. Leerink Partners restated a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.4 %

REGN stock traded down $26.59 during midday trading on Thursday, reaching $755.92. The stock had a trading volume of 394,565 shares, compared to its average volume of 526,043. The firm has a market cap of $83.07 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals has a twelve month low of $753.69 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $992.70 and a two-hundred day simple moving average of $1,033.92.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the period. Capital International Investors increased its stake in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares during the period. Swedbank AB bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth $129,257,000. Finally, Epoch Investment Partners Inc. bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth $99,667,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.